**Supplementary Table 2.** **Associations of clinicopathologic characteristics with the IRGs and prognostic signature in ICGC cohort**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Gender** | |  | **Age** | |  | **Tumor stage** | |
| ***t*** | ***p*** | ***t*** | ***p*** | ***t*** | ***p*** |
| RBP2 | 0.186 | 0.853 |  | 34.049 | 0.883 |  | 10.997 | 0.012 |
| MAPT | 1.597 | 0.113 |  | 39.44 | 0.706 |  | 3.982 | 0.263 |
| BIRC5 | -0.449 | 0.654 |  | 38.353 | 0.748 |  | 18.838 | 2.953e-04 |
| ROBO1 | 0.429 | 0.669 |  | 38.092 | 0.757 |  | 7.156 | 0.067 |
| FIGNL2 | 0.723 | 0.471 |  | 49.532 | 0.297 |  | 15.895 | 0.001 |
| IL17D | 0.843 | 0.401 |  | 40.309 | 0.671 |  | 19.834 | 1.837e-04 |
| SPP1 | 0.663 | 0.509 |  | 36.239 | 0.821 |  | 17.43 | 5.764e-04 |
| STC2 | -0.71 | 0.479 |  | 44.377 | 0.498 |  | 8.256 | 0.041 |
| Risk score | 1.15 | 0.253 |  | 44.312 | 0.501 |  | 24.743 | 1.747e-05 |